PubRank

Steven J Swanson

Author PubWeight™ 31.11‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004 3.53
2 Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J Immunol 2007 1.68
3 Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 2008 1.60
4 Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 2007 1.42
5 Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clin Pharmacol 2011 1.40
6 An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods 2005 1.23
7 Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. J Immunol Methods 2010 1.05
8 Identification and inhibition of drug target interference in immunogenicity assays. J Immunol Methods 2010 1.04
9 Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin Chem 2005 0.99
10 Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotype. J Immunol Methods 2012 0.97
11 The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum. J Pharm Biomed Anal 2008 0.96
12 Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J Clin Immunol 2007 0.96
13 Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. Nephrol Dial Transplant 2005 0.88
14 Strategy to confirm the presence of anti-erythropoietin neutralizing antibodies in human serum. J Pharm Biomed Anal 2011 0.86
15 Feasibility of a multiplex flow cytometric bead immunoassay for detection of anti-epoetin alfa antibodies. Clin Vaccine Immunol 2007 0.85
16 Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J Immunol Methods 2005 0.85
17 Current methods for detecting antibodies against erythropoietin and other recombinant proteins. Clin Diagn Lab Immunol 2005 0.84
18 Detection of anti-ESA antibodies in human samples from PRCA and non-PRCA patients: an immunoassay platform comparison. Nephrol Dial Transplant 2011 0.83
19 Impact of matrix-associated soluble factors on the specificity of the immunogenicity assessment. Bioanalysis 2010 0.83
20 Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference. J Immunol Methods 2013 0.81
21 Comparing exponentially weighted moving average and run rules in process control of semiquantitative immunogenicity immunoassays. AAPS J 2009 0.81
22 Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects. Ann Hematol 2010 0.81
23 Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies. J Immunol Methods 2004 0.80
24 Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics. AAPS J 2012 0.79
25 Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Curr Med Res Opin 2003 0.79
26 Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge. Biotechnol Annu Rev 2004 0.78
27 Development and characterization of a human antibody reference panel against erythropoietin suitable for the standardization of ESA immunogenicity testing. J Immunol Methods 2012 0.78
28 Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact. Bioanalysis 2014 0.77
29 Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. Bioanalysis 2013 0.76
30 A step-wise approach for transfer of immunogenicity assays during clinical drug development. AAPS J 2009 0.75
31 Development and validation of a quantitative cell-based bioassay for comparing the pharmacokinetic profiles of two recombinant erythropoietic proteins in serum. J Pharm Biomed Anal 2006 0.75
32 A non-radioactive method for detecting neutralizing antibodies against therapeutic proteins in serum. J Pharm Biomed Anal 2007 0.75
33 A novel method for detecting neutralizing antibodies against therapeutic proteins by measuring gene expression. J Immunol Methods 2006 0.75